-
collapse
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Multiple Ascending Doses in Young and Elderly Healthy Volunteers
-
collapse
A randomised, double-blind, placebo-controlled, two-way crossover, single-centre methodologhy study in healthy subjects to evaluate the effect of oral dosing with AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS
-
collapse
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 after Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers including food effect
-
collapse
A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels
-
collapse
A Healthy Volunteer Study to Evaluate Reversibility of Induced Impairment of Cognition
-
collapse
A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy and in Combination with Paclitaxel in Japanese Patients with Advanced Solid Malignancies
-
collapse
Interventions study for the control of diabetes mellitus type 2 in obese women
-
collapse
Protocol for the specified clinical experience investigation on the single use of Casodex Tablet 80 mg
-
collapse
A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE
-
collapse
A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution After Administration of Multiple Ascending Doses for 12 Days in Young and Elderly Healthy Japanese Volunteers
